ArticleLife (Basel, Switzerland)2025
Beta-Blocker Use and Risk of Hip Arthroplasty in Osteoarthritis: A Retrospective Electronic Health Record Study.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to determine whether prior use of a beta blocker (BB) is associated with the three-year risk of total hip arthroplasty after being diagnosed with osteoarthritis of the hip and compare risks across BB subtypes.
methodsThrough the TriNetX database, patients with hip OA were included and further divided into the with- and without-BB cohorts. BB users were defined as patients with prescriptions between 1 day and 1 year before hip OA diagnosis and at least one refill afterward. The index date was defined as the diagnosis date of hip OA. Moreover, the BB cohorts were split to evaluate the difference between different types of beta-blocking agents. After propensity score matching, a three-year risk of undergoing THA was calculated.
resultsA total of 313,430 patients were involved in this study, including 23,580 with BB usage, and 289,850 without. After propensity score matching, 23,096 patients remained in each cohort. For the with- and without-BB cohort, the average ages were 69 ± 11.9 and 63.3 ± 11.4, with a majority being female (52.4% vs. 56%). After the three-year follow-up, the use of BBs (2333 vs. 1539, HR = 1.494; 95% C.I. = 1.4-1.593) was associated with a higher risk of undergoing THA. Furthermore, among the three types of BBs, the use of alpha-BBs showed the highest hazard ratio when compared to the without-BB cohort (788 vs. 470, HR = 1.639; 95% C.I. = 1.462-1.837).
conclusionsThese findings suggest a potential association between BB use and hip arthroplasty in OA patients, warranting further investigation rather than immediate changes in clinical practice. Exploration into the detailed mechanisms is warranted and merits investigation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.